74,225 results match your criteria Lung Cancer Non-Small Cell


Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.

J Neurosurg 2019 Feb 15:1-6. Epub 2019 Feb 15.

1Department of Neurosurgery, Yale New Haven Hospital, New Haven, Connecticut.

OBJECTIVEConcurrent use of anti-PD-1 therapies with stereotactic radiosurgery (SRS) have been shown to be beneficial for survival and local lesional control in melanoma patients with brain metastases. It is not known, however, if immunotherapy (IT) confers the same outcome advantage in lung cancer patients with brain metastases treated with SRS.METHODSThe authors retrospectively reviewed 85 non-small cell lung cancer (NSCLC) patients with brain metastases who were treated with SRS between January 2006 and December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3171/2018.10.JNS181371DOI Listing
February 2019

p38 MAP kinases: plausible diagnostic and prognostic serum protein marker of non small cell lung cancer.

Exp Mol Pathol 2019 Feb 13. Epub 2019 Feb 13.

Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India. Electronic address:

Introduction: p38 MAPK signaling molecules plays a dual role in cancer, both progression and suppression. Elevated expression of p38α was reported in lung cancer tissue in rat model. Our objective was to explore the concentration of all 4 isoforms of p38MAPK in serum of Non Small Cell Lung Cancer (NSCLC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexmp.2019.01.009DOI Listing
February 2019

Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group.

Radiol Med 2019 Feb 15. Epub 2019 Feb 15.

Department of Oncology Radiation Therapy Unit, Careggi University Hospital, Florence, Italy.

Purpose: To investigate the role of radiotherapy (RT) in the management of EGFR- or ALK-mutated metastatic non-small cell lung cancer (NSCLC) treated with TKI.

Materials And Methods: Clinical data of 106 patients (pts) from five Institutions treated with RT concomitant to TKI were retrospectively revised. Overall survival (OS) and toxicities were analyzed as endpoints of the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11547-019-00999-wDOI Listing
February 2019

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Cancer Immunol Immunother 2019 Feb 15. Epub 2019 Feb 15.

CureVac AG, Tübingen, Germany.

CV9201 is an RNActive-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa dose-escalation trial, 46 patients with locally advanced (n = 7) or metastatic (n = 39) NSCLC and at least stable disease after first-line treatment received five intradermal CV9201 injections (400-1600 µg of mRNA). The primary objective of the trial was to assess safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02315-xDOI Listing
February 2019

Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous.

Radiat Oncol 2019 Feb 15;14(1):33. Epub 2019 Feb 15.

Department of Radiation Oncology, Miami Cancer Institute, Miami, FL, USA.

Background: Different management options exist for patients with brain metastases from non-small cell lung cancer (NSCLC), patients whose treatment with whole brain radiotherapy (WBRT) has become more controversial over the last decade. It is not trivial to find the optimal balance of over- versus undertreatment in these patients. Several recent trials, including the randomized QUARTZ trial now influence the decision to recommend or withhold WBRT for patients with unfavorable prognosis, and similarly, for favorable prognosis patients, the balance between radiosurgery alone or WBRT has become a nuanced decision. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13014-019-1237-9DOI Listing
February 2019

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, ON, Canada.

Background: KRAS and TP53 are common mutations in non-small-cell lung cancer (NSCLC). The Lung Adjuvant Cisplatin Evaluation Biological Program group found adjuvant chemotherapy to be deleterious in patients with coexisting KRAS/TP53 mutations.

Patients And Methods: To validate these results, patients with NSCLC tested for KRAS and TP53 mutations and receiving chemotherapy for any stage NSCLC were selected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.009DOI Listing
December 2018

CHISELing a path forward in the treatment of early-stage non-small-cell lung cancer.

Lancet Oncol 2019 Feb 12. Epub 2019 Feb 12.

Division of Radiation Oncology, London Health Sciences Centre, London, ON N6A4L6, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30953-7DOI Listing
February 2019

Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.

Lancet Oncol 2019 Feb 12. Epub 2019 Feb 12.

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

Background: Stereotactic ablative body radiotherapy (SABR) is widely used to treat inoperable stage 1 non-small-cell lung cancer (NSCLC), despite the absence of prospective evidence that this type of treatment improves local control or prolongs overall survival compared with standard radiotherapy. We aimed to compare the two treatment techniques.

Methods: We did this multicentre, phase 3, randomised, controlled trial in 11 hospitals in Australia and three hospitals in New Zealand. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30896-9DOI Listing
February 2019

Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers.

Int J Mol Sci 2019 Feb 14;20(4). Epub 2019 Feb 14.

Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw 50-368, Poland.

Background: The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association between PD-L1 expression and clinicopathological features is still unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20040824DOI Listing
February 2019

Tumoral NOX4 recruits M2 tumor-associated macrophages via ROS/PI3K signaling-dependent various cytokine production to promote NSCLC growth.

Redox Biol 2019 Feb 6;22:101116. Epub 2019 Feb 6.

Department of Pharmacology, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China; Guangzhou Key Laboratory of Construction and Application of New Drug Screening Model Systems, Guangdong Pharmaceutical University, Guangzhou 510006, China; Key Laboratory of New Drug Discovery and Evaluation of Ordinary Universities of Guangdong Province, Guangdong Pharmaceutical University, Guangzhou 510006, China. Electronic address:

M2-type tumor-associated macrophages (TAMs) infiltration contributes to cancer malignant progression. However, the mechanisms for controlling recruitment and M2 polarization of macrophages by cancer cells are largely unclear. NADPH oxidase 4 (NOX4) is abundantly expressed in non-small cell lung cancer (NSCLC) and mediates cancer progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.redox.2019.101116DOI Listing
February 2019

Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.

Cancer Med 2019 Feb 14. Epub 2019 Feb 14.

Respiratory Department of Chinese PLA General Hospital, Beijing, China.

Liquid biopsy has provided an efficient way for detection of gene alterations in advanced non-small-cell lung cancer (NSCLC). However, the correlation between systematic determination of somatic genomic alterations in liquid biopsy and tumor biopsy still remained unclear, and the concordance rate between cell-free DNA (cfDNA) and matched tumor tissue DNA needs to be increased. A prospective study was performed to detect differences in genetic profiles of cfDNA in sputum, plasma, urine, and tumor tissue from 50 advanced NSCLC patients in parallel by the same next-generation sequencing (NGS) platform. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1935DOI Listing
February 2019

Prognostic Impact of Tumor Spread Through Air Spaces in Non-small Cell Lung Cancers: a Meta-Analysis Including 3564 Patients.

Pathol Oncol Res 2019 Feb 14. Epub 2019 Feb 14.

Department of Thoracic Surgery, Hebei Provincal General Hospital, 348,West He-Ping Road, Shijiazhuang, 050051, Hebei Province, People's Republic of China.

Surgical resection is the most effective treatment for early stage lung adenocarcinoma. However, the rate of 5-year postoperative recurrence reaches 30%, Spread Through Air Spaces(STAS) is a recently described novel invasive pattern of lung cancer, According to the 2015 WHO classification. STAS is defined as"micropapillary clusters, solid nests, or single cells spreading within air spaces beyond the edge of the main tumor, However, the prognostic role of STAS in lung cancer is not known, The aim of the current study is to evaluate the association between STAS and clinical outcome of lung cancer patients after surgical resection through a meta-analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-019-00616-1DOI Listing
February 2019

Influence of Mutation on Survival in Patients With Advanced -Mutant Non-Small-Cell Lung Cancer.

JCO Precis Oncol 2018 31;2018. Epub 2018 Aug 31.

University of Pennsylvania, Philadelphia, PA.

Purpose: mutation (MT) in epidermal growth factor receptor () -MT non-small cell lung cancer (NSCLC) is associated with poor response to targeted therapy; however, its impact on survival is not clearly established.

Patients And Methods: We performed an analysis of patients with stage IV MT NSCLC with available gene sequencing data. Associations between baseline characteristics; molecular profile, including MT; and survival outcomes were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.18.00107DOI Listing

Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy.

South Asian J Cancer 2019 Jan-Mar;8(1):65-68

Department of Medical Oncology, Max Super Speciality Hospital, New Delhi, India.

Context: The immune checkpoint inhibitors (ICIs) nivolumab and pembrolizumab have shown dramatic efficacy with low toxicity in international studies of advanced solid cancers. No published Indian experience with ICIs exist other than isolated case reports.

Aims: The aim of this study is to evaluate real-world data about the efficacy and toxicity of ICIs in advanced solid cancers among Indian patients who have progressed on one or more prior lines of chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/sajc.sajc_167_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348784PMC
February 2019

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment.

Cancer Biol Med 2018 Nov;15(4):443-451

Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.

Objective: Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-Kit, and c-MET; therefore, it exhibits both antitumor and anti-angiogenetic activities. A phase III trial has shown that anlotinib improved progression-free survival (PFS) and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC), who presented with progressive disease or intolerance after standard chemotherapy. This study aimed to analyze the characteristics of patients receiving anlotinib treatment to determine the dominant populations who are fit for the treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372914PMC
November 2018

PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs.

Cancer Biol Med 2018 Nov;15(4):434-442

Department of General and Oncological Pulmonology, University Clinical Hospital Norbert Barlicki, Medical University of Lodz, Lodz 50243, Poland.

Objective: Epidermal growth factor receptor (EGFR) activation was reported to upregulate programmed death-ligand 1 (PD-L1) expression in lung cancer cells and subsequently contribute to immune escape, indicating its critical role in EGFR-driven lung tumors. This study characterized PD-L1 expression in patients with surgically resected EGFR-mutant non-small cell lung cancer (NSCLC). The effect of PD-L1 expression on clinical outcomes was also investigated in advanced EGFR-mutant NSCLC treated with EGFR-tyrosine kinase inhibitors (TKIs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372913PMC
November 2018

[Efficacy and Safety of Gefitinib as First-Line Chemotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer(NSCLC)].

Gan To Kagaku Ryoho 2019 Jan;46(1):55-59

Dept. of Respiratory/Medical Oncology, Tokyo Metropolitan Tama Medical Center.

Epidermalgrowth factor receptor tyrosine kinase inhibitor(EGFR-TKI)is the first choice for the treatment of EGFR mutation- positive advanced non-small cell lung cancer(NSCLC). There have been few reports on the efficacy and safety of gefitinib in elderly patients with EGFR mutation-positive advanced NSCLC. We retrospectively assessed the efficacy and safety of gefitinib as first-line chemotherapy in 22 patients with advanced NSCLC aged 75 years or older and who were treated with gefitinib. Read More

View Article

Download full-text PDF

Source
January 2019

[Outcome of Limited Resection for Early Stage Non-small Cell Lung Cancer].

Kyobu Geka 2019 Jan;72(1):32-37

Department of Thoracic Surgery, Kansai Medical University, Hirakata, Japan.

Objectives: Recent advancement in detection of small-sized early-stage lung cancer has made limited lung resection with curative intent a practical and vital option. In this retrospective study, we investigated the validity of choice of procedures at our institute with examining the survival outcomes of lung cancer patients who underwent surgery.

Methods: Data from consecutive patients with cTanyN0M0 lung cancer who underwent surgery between January 2006 and December 2012 were extracted by chart review, and the overall and recurrence-free survivals of the patients operated by wedge resection, by segmentectomy and by lobectomy were compared using the univariate and multivariate Cox proportional hazard model. Read More

View Article

Download full-text PDF

Source
January 2019

[Surgical Outcome of Sublobar Resection in High-risk Patients with Non-small Cell Lung Cancer].

Kyobu Geka 2019 Jan;72(1):17-22

Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Hidaka, Japan.

Objectives: Pulmonary lobectomy is the standard surgical procedure for resectable non-small cell lung cancer (NSCLC), while sublobar resection is an important surgical alternative for high-risk patients with comorbidities. We evaluated the treatment outcome and prognostic factors of sublobar resection in high-risk patients with NSCLC.

Methods: Eighty three high-risk patients who underwent compromised sublobar resection for clinical-N0 NSCLC with a solid appearance were retrospectively reviewed. Read More

View Article

Download full-text PDF

Source
January 2019

A Variant of a Killer Cell Immunoglobulin-like Receptor is Associated with Resistance to PD-1 Blockade in Lung Cancer.

Clin Cancer Res 2019 Feb 14. Epub 2019 Feb 14.

Biomedicine, University of Basel

Purpose: PD-(L)1 blocking antibodies have clinical activity in metastatic non-small cell lung cancer (NSCLC) and mediate durable tumor remissions. However, the majority of patients are resistant to PD-(L)1 blockade.Understanding mechanisms of primary resistance may allow prediction of clinical response and identification of new targetable pathways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3041DOI Listing
February 2019

Prognostic Value of RASSF1A Methylation Status in Non-Small Cell Lung Cancer (NSCLC) Patients: A Meta-Analysis of Prospective Studies.

Biomarkers 2019 Feb 15:1-19. Epub 2019 Feb 15.

b School of Public Health , Anhui Medical University , Hefei , 230032 , Anhui, China.

Objective Ras association domain family 1A (RASSF1A) has been regarded as a biomarker predicting the prognosis of non-small cell lung cancer (NSCLC), but previous findings are inconsistent. This meta-analysis of prospective studies aimed to assess the value of RASSF1A methylation in predicting the prognosis of NSCLC patients. Methods Studies were searched in PubMed and Web of Science. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1354750X.2019.1583771DOI Listing
February 2019

Pneumatosis intestinalis after molecular targeted therapy.

World Neurosurg 2019 Feb 11. Epub 2019 Feb 11.

Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:

Background: Pneumoperitoneum after surgical manipulation of the abdomen implies a perforation. Rare cases of non-operated cancer patients, largely with gastrointestinal or genitourinary cancers, have been noted to have radiological findings of pneumatosis intestinalis and/or pneumoperitoneum as a complication of molecular-targeted therapy (MTT) without confounding factors for perforation. We present a patient with a cranial malignancy treated with bevacizumab who subsequently manifested with pneumatosis intestinalis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18788750193033
Publisher Site
http://dx.doi.org/10.1016/j.wneu.2019.01.225DOI Listing
February 2019
1 Read

Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR-TKI therapy: CAURAL brief report.

J Thorac Oncol 2019 Feb 11. Epub 2019 Feb 11.

Thoracic Oncology Program, Vanderbilt University Medical Center, Nashville, TN, USA.

Introduction: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Durvalumab is an anti-PD-L1 monoclonal antibody. The Phase III open-label CAURAL trial (NCT02454933) investigated osimertinib plus durvalumab versus osimertinib monotherapy in patients with EGFR-TKI sensitizing and T790M mutation-positive advanced non-small cell lung cancer (NSCLC) and disease progression following EGFR-TKI therapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864193010
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2019.02.001DOI Listing
February 2019
1 Read
5.282 Impact Factor

Nm23-H1 inhibits hypoxia induced epithelial-mesenchymal transition and stemness in non-small cell lung cancer cells.

Biol Chem 2019 Feb 14. Epub 2019 Feb 14.

Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu, China.

The Nm23 gene has been acknowledged to play a crucial role in lung cancer metastasis inhibitory cascades controlled by multiple factors. Low expression or allelic deletion of nm23-H1 is strongly linked to widespread metastasis and poor differentiation of non-small cell lung cancer (NSCLC). In this study, nm23-H1 was down regulated in epithelial-mesenchymal transition (EMT) and stemness enhancement under cobalt chloride (CoCl2)-induced hypoxia in NSCLC cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/hsz-2018-0351DOI Listing
February 2019

Lesser Known Facts of Small Cell Lung Cancer.

J Comput Assist Tomogr 2019 Feb 11. Epub 2019 Feb 11.

From the University Hospitals-Cleveland Medical Center, Cleveland, OH.

Until recently, the treatment of small cell lung cancer (SCLC), a malignancy classically described as having a robust response to first-line therapy with near-universal recurrence, has remained relatively unchanged. Advancements in the management of SCLC have lagged behind those seen for non-small cell lung cancers. As the era of precision medicine and targeted immunotherapy evolves, radiologists must be familiar with the modern treatment paradigms of SCLC and associated imaging patterns, including classic and nonclassic appearances of treatment complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RCT.0000000000000847DOI Listing
February 2019

Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.

Anticancer Drugs 2019 Feb 12. Epub 2019 Feb 12.

Departments of Medicine, Division of Oncology.

The mesenchymal-to-epithelial transition (MET) gene is altered and becomes a driver mutation in up to 5% of non-small-cell lung cancer (NSCLC). We report our institutional experience treating patients with MET exon 14 skipping (METex14) mutations, including responses to the MET inhibitors crizotinib and cabozantinib. We identified cases of NSCLC with METex14 mutations using an institutionally developed or commercial next-generation sequencing assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000765DOI Listing
February 2019

Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer.

Thorac Cancer 2019 Feb 14. Epub 2019 Feb 14.

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Background: The aim of this study was to evaluate the usefulness of the presence of malignant pleural effusion (MPE) as a negative predictor of anti-PD-1 antibody efficacy.

Methods: A retrospective review of patients with advanced or recurrent non-small cell lung cancer treated with an anti-PD-1 antibody between December 2015 and March 2018 at the National Cancer Center Hospital, Japan, was conducted. Progression-free survival (PFS) and overall survival (OS) were compared between patients with and without MPE. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1759-7714.13004
Publisher Site
http://dx.doi.org/10.1111/1759-7714.13004DOI Listing
February 2019
1 Read

Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.

Cancer Med 2019 Feb 14. Epub 2019 Feb 14.

Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.

Aims: This real-world study is conducted to evaluate the efficacy and safety of recombinant human endostatin (rh-endostatin) combined with chemotherapy as first-line treatment for non-driver genes mutation non-small cell lung cancer (NSCLC) patients, and establish evidence-based optimal regimen for rh-endostatin.

Patients And Methods: Using propensity score matching (cut-off: 0.01), 88 patients were eligible for our study, 34 of which received platinum-based chemotherapy alone (chemotherapy group), 54 patients received platinum-based chemotherapy plus rh-endostatin (rh-endostatin group). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2014DOI Listing
February 2019

Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer.

Cancer Chemother Pharmacol 2019 Feb 14. Epub 2019 Feb 14.

Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Purpose: A prospective, multicenter, large-scale cohort with a nested case-control study (NCT00252759) was conducted to identify and quantify risk factors for interstitial lung disease (ILD) in Japanese patients with non-small-cell lung cancer who received gefitinib. This study reports the association between gefitinib exposure and the occurrence of ILD.

Methods: A total of 1891 gefitinib plasma concentrations from 336 patients were measured after first dose, at steady state, and at time of ILD occurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03788-4DOI Listing
February 2019

Higher Anti-angiogenesis Activity, Better Cellular Uptake and Longer Half-life of a Novel Glyco-modified Endostatin by Polysulfated Heparin.

Curr Pharm Biotechnol 2018 ;19(12):996-1004

National Glycoengineering Research Center, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China.

Background: Endostatin (ES) is a promising anti-angiogenesis protein and has been approved for the treatment of non-small cell lung cancer, but short half-life, poor stability and nonspecific delivery caused great pain to patients and produced unsatisfactory treatment effectiveness.

Objective: In this work, in order to overcome these disadvantages, ES was covalently modified by polysulfated heparin (PSH) with the expectancy of longer half-life, higher anti-angiogenesis activity and better cellular uptake.

Methods: To characterize the cellular uptake, flow cytometry and confocal laser scanning microscopy were used to study the intracellular localization of fluorescein isothiocyanate-labeled ES and PSH-ES in EAhy926 endothelial cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389201020666181120164753DOI Listing
January 2018

Uniportal video-assisted thoracoscopic left S4 anatomical segmentectomy.

Thorac Cancer 2019 Feb 13. Epub 2019 Feb 13.

Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.

Uniportal video-assisted thoracic surgery (VATS) segmentectomy is a demanding technique but is safe and feasible in selected patients and confers favorable efficacy. It presents an acceptable alternative to conventional VATS. Lingulectomy is usually performed with left S4 + S5 segmentectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13005DOI Listing
February 2019

Patterns of follow-up care after curative radiotherapy ± chemotherapy for stage I-III non-small cell lung cancer.

Asia Pac J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

South Western Sydney Clinical School, University of NSW, NSW, Australia.

Objectives: To describe patterns of follow-up care for non-small cell lung cancer patients treated with curative radiotherapy and to evaluate the role of routine imaging.

Materials And Methods: We retrospectively analyzed follow-up care of patients with stage I-III non-small cell lung cancer treated with curative radiotherapy (minimum dose of 50 Gy) between 2007 and 2011 at three Sydney institutions. Patient demographics, tumor characteristics and treatment factors were collected from oncology and hospital records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13127DOI Listing
February 2019

A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC.

Pathol Oncol Res 2019 Feb 14. Epub 2019 Feb 14.

Department of Oncology Radiotherapy, First Affliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, People's Republic of China.

Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation have different clinicopathological characteristics compared with EGFR wild type NSCLC. A growing number of studies focused on the relevance between EGFR mutation status and brain metastases (BM) in NSCLC, but it remains controversial. Therefore, this study performed a comprehensive meta-analysis to untangle this issue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-019-00598-0DOI Listing
February 2019
1.806 Impact Factor

Inhibition of FAK Signaling Elicits Lamin A/C-Associated Nuclear Deformity and Cellular Senescence.

Front Oncol 2019 30;9:22. Epub 2019 Jan 30.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Focal adhesion kinase (FAK) is a non-receptor kinase that facilitates tumor aggressiveness. The effects of FAK inhibition include arresting proliferation, limiting metastasis, and inhibiting angiogenesis. PF-573228 is an ATP-competitive inhibitor of FAK. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fonc.2019.00022/
Publisher Site
http://dx.doi.org/10.3389/fonc.2019.00022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363943PMC
January 2019
1 Read

PARP Inhibitors: Extending Benefit Beyond BRCA Mutant Cancers.

Clin Cancer Res 2019 Feb 13. Epub 2019 Feb 13.

Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center

A mounting body of evidence now indicates that PARP inhibitors have the potential to be used as a foundation for both monotherapy and combination strategies across a wide spectrum of molecular backgrounds and tumor types. While PARP inhibitors as a class display many similarities, critical differences in structure can translate into differences in tolerability and antitumor activity that have important implications for the clinic. Furthermore, while PARP inhibitors have demonstrated a clear role in treating tumors with underlying homologous recombination deficiencies, there is now biological and early clinical evidence to support their use in other molecular subsets of cancer, including tumors associated with high levels of replication stress such as small cell lung cancer. Read More

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-0968DOI Listing
February 2019
1 Read

The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis.

BMC Cancer 2019 Feb 13;19(1):145. Epub 2019 Feb 13.

Department of Surgical Oncology, First Hospital of China Medical University, Shenyang, 110001, Liaoning Province, China.

Background: The brain is a common site for metastasis in non-small-cell lung cancer (NSCLC). This study was designed to evaluate the relationship between the mutational of the epidermal growth factor receptor (EGFR) and overall survival (OS) in NSCLC patients with brain metastases.

Methods: Searches were performed in PubMed, EmBase, and the Cochrane Library to identify studies evaluating the association of EGFR mutation with OS in NSCLC patients through September 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5331-zDOI Listing
February 2019
1 Read

Treatment exceeds expectations in a patient with non-small cell lung adenocarcinoma with an EGFR exon 20 mutation.

J Oncol Pharm Pract 2019 Feb 13:1078155219829810. Epub 2019 Feb 13.

2 Smilow Cancer Center, Yale-New Haven at Saint Francis, Hartford, CT, USA.

Non-small cell lung adenocarcinoma is the most common type of lung cancer but is often difficult to treat. New treatment options have emerged with the class of tyrosine kinase inhibitors, but it has been found that certain genetic mutations in the epidermal growth factor receptor (EGFR) receptor are not as sensitive to this treatment as others. We present a case of a 78-year-old man who was diagnosed with stage IV non-small cell lung adenocarcinoma with an EGFR exon 20 mutations treated with pemetrexed, nivolumab, and then docetaxel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155219829810DOI Listing
February 2019
1 Read

Inference on covariate effect types for treatment effectiveness in a randomized trial with a binary outcome.

Authors:
Yasutaka Chiba

Clin Trials 2019 Feb 13:1740774519828301. Epub 2019 Feb 13.

Clinical Research Center, Kinki University Hospital, Osakasayama, Japan.

Background/aims: Some randomized clinical trials seek to establish covariate effect types that indicate whether a covariate is predictive and/or prognostic, in addition to endpoint evaluation. Here, for a case with a binary outcome, we propose that the covariate effect type should be assessed in terms of four types of potential responses: activated- (always-), inert- (never-), causative-, and preventive-responder.

Methods: We introduce a new concept of covariate effect types differing from the commonly used "prediction" and "prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774519828301DOI Listing
February 2019
1 Read

Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.

Molecules 2019 Feb 12;24(3). Epub 2019 Feb 12.

Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China.

Non-small cell lung cancer (NSCLC) patients carrying an epidermal growth factor receptor (EGFR) mutation are initially sensitive to EGFR-tyrosine kinase inhibitors (TKIs) treatment, but soon develop an acquired resistance. The treatment effect of EGFR-TKIs-resistant NSCLC patients still faces challenges. Cucurbitacin B (CuB), a triterpene hydrocarbon compound isolated from plants of various families and genera, elicits anticancer effects in a variety of cancer types. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1420-3049/24/3/647
Publisher Site
http://dx.doi.org/10.3390/molecules24030647DOI Listing
February 2019
1 Read

Effect of intensivist involvement on clinical outcomes in patients with advanced lung cancer admitted to the intensive care unit.

PLoS One 2019 13;14(2):e0210951. Epub 2019 Feb 13.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Bundang-gu, Seongnam, South Korea.

Purpose: Intensive care unit (ICU)-related mortality for lung cancer is ranked highest among the solid tumors and little information exists on the role of intensivists on clinical outcomes. This study aimed to elucidate the intensivist's contribution toward clinical outcomes.

Materials And Methods: Data of advanced lung cancer patients, including stage IIIB or IV non-small cell lung cancer and extensive-stage small cell lung cancer, admitted to the ICU from 2005 to 2016 were analyzed. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210951PLOS
February 2019
1 Read
3.234 Impact Factor

Common Mechanisms Linking Chronic Obstructive Pulmonary Disease and Lung Cancer.

Ann Am Thorac Soc 2018 Dec;15(Supplement_4):S273-S277

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; and Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington.

Chronic obstructive pulmonary disease (COPD) and lung cancer are linked diseases, with both the incidence of and risk of death from non-small cell lung cancer being increased by the presence of COPD. Despite numerous well-performed epidemiological studies having described this link over the past 30 years, the operative mechanisms remain elusive. One of the major obstacles to advancement in the field has been the lack of patient cohorts that have been phenotyped for both COPD and lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1513/AnnalsATS.201808-537MGDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322005PMC
December 2018

Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers.

J Cancer Res Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

General-, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Introduction: Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies.

Materials And Methods: This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-019-02850-1DOI Listing
February 2019

Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.

Cancer Chemother Pharmacol 2019 Feb 13. Epub 2019 Feb 13.

Department of Respiratory Medicine Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-City, Saitama, 350-1298, Japan.

Background: Re-challenge of erlotinib after gefitinib failure is reported to yield some benefit in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation. However, little is known about the re-challenge of afatinib after 1st generate on EGFR tyrosine kinase inhibitor (TKI) failure.

Methods: From May 2015 to August 2018, 62 patients with advanced NSCLC harboring sensitive EGFR mutation received afatinib after gefitinib and/or erlotinib failure at our institution was included in our retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03790-wDOI Listing
February 2019

[Lobectomy vs. radiotherapy for non-small-cell lung cancer patients].

Chirurg 2019 Feb 13. Epub 2019 Feb 13.

Klinik und Poliklinik Allgemein‑, Viszeral- und Tumorchirurgie, Universität zu Köln, Kerpener Straße 62, 50931, Köln, Deutschland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00104-019-0876-6DOI Listing
February 2019

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

Future Oncol 2019 Feb 13. Epub 2019 Feb 13.

Boehringer Ingelheim Pharma GmbH & Co, KG, Germany & Institute of Pharmacology, Johannes Gutenberg-University Mainz, Germany.

A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has 'aggressive disease', as reflected in short time to progression or lack of disease control with initial platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively impact on outcomes with nivolumab in nonsquamous NSCLC with low programmed death-ligand 1 expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0948DOI Listing
February 2019

Assessing the Psychosocial Needs of Newly Diagnosed Patients with Non-Small Cell Lung Cancer: Identifying Factors Associated with Distress.

Psychooncology 2019 Feb 13. Epub 2019 Feb 13.

Department of Medical Oncology, BC Cancer.

Background: The Psychosocial Screen for Cancer (PSSCAN-R) questionnaire is a validated screening tool used to identify the psychosocial needs of patients with cancer. It assesses patients' perceived social supports and psychosocial needs, and the presence of symptoms of depression and anxiety. The study goals were to assess the prevalence and factors associated with distress in patients with newly diagnosed NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pon.5025DOI Listing
February 2019

Is video-assisted thoracoscopy a sufficient approach for mediastinal lymph node dissection to treat lung cancer after neoadjuvant therapy?

Thorac Cancer 2019 Feb 12. Epub 2019 Feb 12.

Department of Thoracic Surgery, Center for Mini-invasive Thoracic Surgery, People's Hospital, Peking University, Beijing, China.

Background: The role of video-assisted thoracoscopic surgery (VATS) in mediastinal lymph node dissection (MLND) for non-small cell lung cancer (NSCLC) following neoadjuvant therapy remains controversial. The aim of this study was to demonstrate the sufficiency of VATS by evaluating perioperative and long-term outcomes.

Methods: Patients with locally advanced NSCLC and treated with radical surgery after neoadjuvant therapy were identified in our database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.12999DOI Listing
February 2019

Annexin 1-nuclear factor-κB-microRNA-26a regulatory pathway in the metastasis of non-small cell lung cancer.

Thorac Cancer 2019 Feb 12. Epub 2019 Feb 12.

Department of Pathology, School of Basic Medical Science, Guangzhou Medical University, Xinzao, China.

Background: Annexin 1 (ANXA1) expression is associated with the malignant tumor phenotype, making it an attractive therapeutic target. However, little is known about the regulation of ANXA1 in non-small cell lung cancer (NSCLC).

Methods: We investigated the biological roles of ANXA1 in tumor growth, migration, and invasion, and explored the possibility of ANXA1 as a potential therapeutic target for the treatment of NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.12982DOI Listing
February 2019

Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?

J Cancer Res Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Purpose: To evaluate the prognostic value of FDG PET/CT metabolic parameter compared to clinico-pathological risk factors in surgical margin-negative stage IA non-small cell lung cancer (NSCLC) patients.

Methods: 167 patients with consecutive FDG PET/CT scans from 2009 to 2015 performed for staging of NSCLC stage IA with plans for curative surgery were retrospectively reviewed. Maximum standardized uptake value (SUVmax) of primary tumor and mean SUV of liver were acquired from PET/CT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-019-02858-7DOI Listing
February 2019

A Case of Donor-Transmitted Non-Small Cell Lung Cancer After Liver Transplantation: An Unwelcome Guest.

Oncologist 2019 Feb 12. Epub 2019 Feb 12.

Mayo Clinic Cancer Center, Phoenix, Arizona, USA

Cancer transmission with organ donation has been previously reported with a variety of malignancies and organ transplants. The risk of transmission through organ transplantation from donors with a history of previously treated malignancies has been addressed by guidelines from transplant societies. Herein, we report a case of a patient who developed lung cancer confined to the liver after liver transplantation with no known history of malignancy in the donor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0517DOI Listing
February 2019